US approves first HIV-prevention drug

For the first time, a once-a-day pill which reduces the chance of contracting HIV among high risk groups ‘significantly’ has got green signal in the US, where 1.2 million people are infected by the deadly disease.

The drug, ’Truvada’ can now be used by those at high risk of the infection and anyone who may engage in sexual activity with HIV-infected partners, the Food and Drug Administration (FDA) announced. ‘In two large clinical trials, daily use of the drug was shown to significantly reduce the risk of HIV infection,’ it said on Sunday.

However, some health workers and groups active in the HIV community opposed the approval for the once-a-day pill. There are concerns that circulation of such a drug could engender a false sense of security and mean people will take more risks. There have also been fears that a drug-resistant strain of HIV could develop.

People diagnosed with HIV that without treatment develops into AIDS take antiviral medications to control the infection that attacks their immune system. In a statement, the FDA stressed that the drug should be used as part of a ‘comprehensive HIV prevention plan’, including condom use and regular HIV testing.

An advisory group of health experts recommended approval for the pill in May this year. Truvada, is already backed by the FDA to be taken with existing anti-retroviral drugs for people who have HIV.

Studies have shown that Truvada reduced the risk of HIV in healthy gay men - and among HIV-negative heterosexual partners of HIV-positive people - by between 44 per cent and 73 per cent. ‘In the 80s and early 90s, HIV was viewed as a life-threatening disease. Medical advances have enabled us to treat it as a chronic disease most of the time,’ Debra Birnkrant, director of the Division of Antiviral Products at FDA, said.
Next Story
Share it